The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis.
 
Lucia Masarova
No Relationships to Disclose
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; ARIAD; BiolineRx; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Teva (Inst)
 
Naveen Pemmaraju
No Relationships to Disclose
 
Elias Jabbour
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer
 
Prithviraj Bose
Honoraria - Incyte
Consulting or Advisory Role - Incyte
Research Funding - Celgene
Travel, Accommodations, Expenses - Incyte
 
Maro Ohanian
No Relationships to Disclose
 
Lingsha Zhou
No Relationships to Disclose
 
Sherry Pierce
No Relationships to Disclose
 
Romany Gergis
No Relationships to Disclose
 
Gautam Borthakur
No Relationships to Disclose
 
Zeev Estrov
No Relationships to Disclose
 
Guillermo Garcia-Manero
No Relationships to Disclose
 
Hagop M. Kantarjian
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)
 
Srdan Verstovsek
No Relationships to Disclose
 
Naval Guastad Daver
No Relationships to Disclose